Johnson & Johnson recall: No. 22 in just 19 months
Johnson & Johnson recall involves epilepsy pills. This makes the 22nd Johnson & Johnson recall since September 2009.
Chairman and CEO of Johnson & Johnson William Weldon testifies during a hearing on the Johnson & Johnson recall of children's Tylenol and other children's medicine and the phantom recall of motrin, before the House Oversight and Government Reform Committee on Capitol Hill in Washington Sept. 30, 2010. The company has now issued 22 recalls in the past 19 months.
Zhang Jun/Xinhua/Photoshot/Newscom/File
TRENTON, N.J.
Johnson & Johnson issued yet another recall Thursday, this one for about 57,000 bottles of a widely used epilepsy pill, due to complaints of a chemical odor.
The health care giant said it is recalling two lots of 100-milligram tablets of Topamax, sold between Oct. 19 and Dec. 28, 2010. The lot numbers are OKG110 and OLG222. J&J said fewer than 6,000 of the bottles are believed to still be on the market.
J&J said only that the pills were sold in the U.S. and Puerto Rico.
The New Brunswick, N.J., company has now issued 22 product recalls, involving well over 300 million bottles of medicines, since September 2009.
Many of the recalls involved widely used nonprescription drugs such as Motrin and Children's Tylenol. The reasons have ranged from metal and other contaminants, to nauseating odors and packaging issues. Joint replacement systems so painful they required corrective surgery were also recalled, as were contact lenses that irritated eyes, along with potentially contaminated syringes full of the antipsychotic drug Invega.
RELATED: Eggs. Shrek glasses. Sure, but what was the top recall of 2010?
The high-profile lapses have tugged at J&J's revenue, profit and stock price, as well as its once-stellar reputation.
On Thursday, Johnson & Johnson said it had received four consumer complaints of an odor believed to be a chemical called TBA, or tribromoanisole, a byproduct of a chemical preservative sometimes used on shipping pallets.
J&J said "a very small number of patients have reported temporary gastrointestinal symptoms," but TBA is not considered toxic.
The same issue was linked to some of its previous recalls.
Lost revenue stemming from recalls and the lengthy closure of a plant in suburban Philadelphia reduced J&J's 2010 sales by $900 million.
In the fourth quarter, J&J posted a 12 percent profit decline and a 5.5 percent drop in sales.
The latest bad news for J&J comes just five days before it is scheduled to release first-quarter results.
In January, J&J forecast 2011 earnings per share of about $4.85, well below analysts' expectation of $4.99 a share for 2011.
RELATED: Eggs. Shrek glasses. Sure, but what was the top recall of 2010?